This mutational strategy is aligned with the molecular fingerprints associated with clinical sarcomas: Mutations in the p53 gene are very common in human sarcomas and are detected in 50–70% of STS [25]; and although allelic point mutations of RAS are less common in STS, more than 80% of human UPS display aberrant activation of the RAS/MAPK pathway [51, 52]. The gene discussed is TP53; the disease is sarcoma.